Heidelberg Pharma AG: directors' dealings · Germany · BaFin

About Heidelberg Pharma AG

Heidelberg Pharma AG is a German biopharmaceutical company listed on Xetra/Frankfurt (DAX/MDAX/SDAX) and headquartered in Germany, in Ladenburg near Heidelberg. The company traces its roots back to 1997, when it was founded in Munich as Wilex Biotechnology GmbH. After a restructuring in 2011, the registered office was moved to Ladenburg and the company was renamed Heidelberg Pharma AG. For international investors, this is a classic listed biotech story: a differentiated scientific platform, a pipeline that is still largely pre-commercial, and a business model that depends heavily on financing, partnerships, and milestone-based value creation. Heidelberg Pharma’s core business is antibody-drug conjugates, or ADCs. The company’s proprietary platform is called ATAC, short for Amanitin-based Antibody Conjugates. According to its 2024 annual report, Heidelberg Pharma believes it is the first and, to its knowledge, only company developing amanitin for cancer therapies. In addition to amanitin, the group is extending its technology toolbox with other payloads such as exatecan and immune-stimulating TLR7-based approaches, creating a broader platform strategy across multiple ADC modalities. Research is mainly conducted by Heidelberg Pharma Research GmbH, while the parent company focuses on clinical development, corporate strategy, regulatory affairs, intellectual property, business development, finance, and group functions. The pipeline is centered on HDP-101, the company’s lead asset in hematology, being developed for multiple myeloma and recently advanced further in clinical development. Another important program, HDP-102, reached a key milestone in 2025 when the first patient was dosed in a Phase I study for non-Hodgkin lymphoma. Heidelberg Pharma also retains legacy assets from the former Wilex portfolio, including upamostat and girentuximab, which were out-licensed to partners. These assets are not the main strategic focus, but they provide optionality and reflect the company’s historical evolution. From a competitive standpoint, Heidelberg Pharma is positioned as a specialist innovator rather than a commercial-stage pharma group. It operates in a highly competitive global ADC market populated by much larger and better-capitalized pharmaceutical and biotech players. Its investment case therefore hinges on scientific differentiation, clinical data generation, and the ability to secure external funding and strategic alliances. The company’s geographic base is Germany, but its business model is international by design, with clinical development, scientific presentations, and business partnerships extending well beyond the home market. Recent developments point to a strategic tightening of focus. In 2025 and 2026, Heidelberg Pharma reported further progress for HDP-101, received FDA Fast Track designation for that lead candidate, announced a change in executive leadership with Dr Dongzhou Jeffery Liu becoming CEO, and significantly reduced operating costs while concentrating resources on the lead program after a delayed milestone payment. The company also announced an amendment to its financing arrangement with HealthCare Royalty and the participation of Soleus Capital, while its latest quarterly updates highlighted continued attention to liquidity and cash burn. Overall, HPHA remains a high-risk, high-upside biotech name, but one with a distinct ADC platform and several meaningful clinical and financing catalysts ahead.